lartesertib (M4076) / EMD Serono 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lartesertib (M4076) / EMD Serono
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Recruiting
2
60
Europe, US, RoW
Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Ovarian Cancer
01/28
01/28
NCT04882917: First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

Completed
1
22
Canada, US
M4076
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Advanced Solid Tumors
03/23
03/23
DDRiver Solid Tumors 320, NCT05396833: Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor

Recruiting
1
72
Europe, Canada, US, RoW
Tuvusertib, M1774, Lartesertib, M4076, Avelumab
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
03/26
05/26

Download Options